Pathological analysis and drug discovery for vertebral disc egeneration using Sox90CreERT2 mice

• Project/Area Number: 23791637
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Kyoto University
• Principal Investigator: SO Kazutaka 京都大学, 医学研究科, 助教 (30514038)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: TGF-beta / 椎間板 / 低分子化合物 / 変形性脊椎症 / 遺伝子改変マウス / 創薬

Research Abstract

in situ hybridization and immunohistochemistry showed that TGFBR-II conditional deficient mice had growth and differentiation abnormality of growth plate chondrocytes in endoplates. This abnormality was not improved by IGF-I injection. Next, to discover new drugs for the treatment of vertebral disc degeneration, we screened about 2000 chemical reagents using TGFBR-II null primary chondrocytes, and so far we have not got a targetreagent yet.